XML 40 R27.htm IDEA: XBRL DOCUMENT v3.25.2
Contract Balances, Performance Obligations and Contract Costs
 6 Months Ended
Jul. 31, 2025
Contract Balances, Performance Obligations and Contract Costs  
Contract Balances, Performance Obligations and Contract Costs

Note 19 – Contract Balances, Performance Obligations and Contract Costs

Deferred Revenue

The following table presents the changes in the deferred revenue balance as follows:

​

​

​

​

​

    

Deferred

​

​

Revenue

Balance at January 31, 2025

 

105,208

Recognition of previously deferred revenue

 

(61,934)

Deferral of revenue

 

70,194

Increases from business combinations, net

 

3,296

Effect of movements in foreign exchange

 

1,411

Balance at July 31, 2025

 

118,175

Current

​

116,870

Long-term

​

1,305

​

Performance Obligations

As of July 31, 2025, approximately $553.8 million of revenue is expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. We expect to recognize revenue on approximately 80% of these remaining performance obligations over the next 24 months with the balance recognized thereafter.

Contract Assets

The following table presents the changes in the contract assets balance as follows:

​

​

​

​

​

    

Contract

​

​

Assets

Balance at January 31, 2025

 

7,421

Transfers to trade receivables from contract assets

 

(2,627)

Increases as a result of revenue recognized during the period, net of amounts transferred to trade receivables

 

456

Effect of movements in foreign exchange

 

25

Balance at July 31, 2025

 

5,275

​

Contract Costs

Capitalized contract costs net of accumulated amortization is $ 21.9 million at July 31, 2025 ($19.0 million at January 31, 2025). Capitalized contract costs are amortized consistent with the pattern of transfer to the customer for the goods and services to which the asset relates. For the three and six month periods ended July 31, 2025, the amount of amortization included in sales and marketing expenses was $2.1 million and $4.1 million, respectively, and $1.7 million and $3.4 million for the same periods in fiscal 2025, respectively. For both the three and six month periods ended July 31, 2025 and July 31, 2024, there was no impairment loss in relation to the capitalized contract costs.